CX3CR1 and atherosclerosis: Further, examining the impact of CX3CR1–CX3CL1 axis inhibition via a soluble CX3CR1 agonist revealed improved atherosclerosis via the inhibition of monocyte-endothelial cell interaction and suggested this approach as a treatment strategy for atherosclerosis [141].